Hybrid risk adjustment for pharmaceutical benefits

Manuel García-Goñi (), Pere Ibern and José María Inoriza

Economics Working Papers from Department of Economics and Business, Universitat Pompeu Fabra

Abstract: This paper analyses the application of hybrid risk adjustment versus either prospective or concurrent risk adjustment formulae in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organization in Catalonia during years 2002 and 2003. We apply a mixed formula and find that a hybrid risk adjustment model increases incentives for efficiency in the provision of low risk individuals at health organizations not only as a whole but also at each internal department compared to only prospective models by reducing within-group variation of drug expenditures.

Keywords: Drug expenditure; hybrid risk-adjustment; morbidity; clinical risk groups (search for similar items in EconPapers)
JEL-codes: I18 (search for similar items in EconPapers)
Date: 2009-01
New Economics Papers: this item is included in nep-hea
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://econ-papers.upf.edu/papers/1139.pdf Whole Paper (application/pdf)

Related works:
Journal Article: Hybrid risk adjustment for pharmaceutical benefits (2009)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:upf:upfgen:1139

Access Statistics for this paper

More papers in Economics Working Papers from Department of Economics and Business, Universitat Pompeu Fabra
Bibliographic data for series maintained by ( this e-mail address is bad, please contact ).